Roche has claimed a breakthrough designation from the FDA for a cancer test that combines an antibody assay with artificial ...

Ono Pharma’s U.S. arm is laying off 83 staffers at its site in Cambridge, Massachusetts. | The affected Cambridge site is Ono ...

Senseonics and newcomer pump developer Sequel Med Tech have a plan to connect their diabetes technologies, with the goal of ...

Eli Lilly is paying $13 million upfront, with $1 billion in biobucks up for grabs, for the opportunity to develop AI-designed ...

An approval decision for Stealth BioTherapeutics’ investigational treatment for an ultra-rare genetic disease has been ...

Octagon Therapeutics has thrown in the towel. The Novo Nordisk-allied autoimmune disease biotech is winding down after deprioritizing its lead program and running into unresolved biology questions.

AstraZeneca has axed three MedImmune legacy monoclonal antibody drugs from its neuroscience pipeline in a first-quarter clear ...

Novartis has done a little spring cleaning, sweeping a phase 2 osteoarthritis prospect and first-in-human radioconjugate out of its pipeline after assessing evidence on the programs. | Novartis has ...

Oberland Capital Management is pumping some new life into Biohaven, striking a unique investment deal worth up to $600 ...

Three Senate Democrats called for an investigation into the developers of brain-computer interface devices, including ...

Ferrer’s R&D work focuses on neurological and pulmonary diseases, and the Spanish pharma has bought into ALS assets in the ...